Drug application
STAVUDINE; LAMIVUDINE; EFAVIRENZ (STAVUDINE, LAMIVUDINE, EFAVIRENZ)
Drugs@FDA NDA 022097 · STRIDES ACROLAB
Key facts
| Drug name | STAVUDINE; LAMIVUDINE; EFAVIRENZ |
|---|---|
| Active ingredients | STAVUDINE, LAMIVUDINE, EFAVIRENZ |
| Application type | NDA |
| Application number | 022097 |
| Company | STRIDES ACROLAB |
| Dosage forms | TABLET, ORAL |
| Strength | 40MG; 150MG; 600MG |
| Marketing status | None (Tentative Approval) |
| Reference listed drug | No |
| Latest submission class | Type 4 - New Combination |
| Latest submission status date | Jun 1, 2007 |
At a glance
- 1–9 Submissions
- None Label versions
- 1–9 Products
- None Therapeutic equivalents
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA applications
Drugs@FDA covers FDA-approved brand-name and generic drugs and therapeutic biologics, with their applications (NDA, ANDA or BLA), products, submissions and labels.